Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
NCT05110001 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 330
Last updated 2026-01-30
Summary
Rose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is an international, randomized, doubled masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial treatment plus cross-linking with rose Bengal (RB-PDT).
Patients presenting to one of the Aravind Eye Hospitals in India or to the Federal University of São Paulo ophthalmology clinic in Brazil with either smear or culture positive fungal or acanthamoeba keratitis or smear and culture negative corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be randomized to one of two treatment groups:
Group 4, Sham RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT
Group 5, RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT.
Conditions
- Acanthamoeba Keratitis
- Fungal Keratitis
Interventions
- DRUG
-
Moxifloxacin Ophthalmic
Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
- DRUG
-
Chlorhexidine Gluconate
Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.
- DRUG
-
Natamycin
Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.
- DRUG
-
Rose Bengal
Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
- OTHER
-
Placebo
Study participants receive sham RB-PDT within 48 hours of randomization. Participants will receive a 30-minute loading dose of topical balanced salt solution which will be applied in 5-minute intervals to the de-epithelialized cornea. A pen light covered with a green filter will be used for 15 minutes. Repeat cornea culture will be collected 30 minutes after the sham procedure.
Sponsors & Collaborators
-
Aravind Eye Care System
collaborator OTHER -
National Eye Institute (NEI)
collaborator NIH - collaborator OTHER
-
Federal University of São Paulo
collaborator OTHER -
University of California, San Francisco
lead OTHER
Principal Investigators
-
Tom Lietman, MD · University of California, San Frnasco
-
Jennifer Rose-Nussbaumer, MD · Stanford University
-
Nicole Varnado, MPH · Stanford University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-08-03
- Primary Completion
- 2024-12-14
- Completion
- 2025-06-30
Countries
- Brazil
- India
Study Locations
More Related Trials
-
Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial
NCT05162625 ·Status: UNKNOWN ·Phase: PHASE2
-
Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis
NCT05079854 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Topical Fluoroquinolones on Epithelial Wound Healing After PRK
NCT00569881 ·Status: COMPLETED
-
Topical Infliximab in Eyes With Penetrating Keratoplasty
NCT05180994 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Steroids and Cross-linking for Ulcer Treatment
NCT04097730 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Post Operative Inflammation in LASIK Surgery
NCT00330824 ·Status: COMPLETED ·Phase: NA
-
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection
NCT02068430 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation
NCT01603030 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
NCT05255107 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
NCT01189864 ·Status: TERMINATED
-
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
NCT04894110 ·Status: COMPLETED ·Phase: PHASE1
-
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
NCT01024322 ·Status: TERMINATED
-
Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C
NCT00346489 ·Status: COMPLETED ·Phase: PHASE4
-
The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma
NCT02388360 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
NCT03244072 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery
NCT01515826 ·Status: WITHDRAWN ·Phase: PHASE3
-
Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
NCT03274895 ·Status: COMPLETED ·Phase: PHASE3
-
A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery
NCT01296542 ·Status: COMPLETED ·Phase: PHASE4
-
Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty
NCT00485108 ·Status: COMPLETED ·Phase: NA
-
Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision
NCT00892918 ·Status: UNKNOWN ·Phase: NA
-
Evaluate the TetraLens, a Tetracaine Releasing Therapeutic Bandage Contact Lens in Patients Undergoing PRK Procedure
NCT06085352 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Fluorometholone Study
NCT07308938 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Measurement of Antioxidant Activity on Postoperative Inflammation in Patients Undergoing Ophthalmic Surgery
NCT05905237 ·Status: COMPLETED
-
Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery
NCT05413980 ·Status: COMPLETED
-
Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery
NCT00575380 ·Status: COMPLETED ·Phase: PHASE4